Motor and cognitive placebo-/nocebo-responses in Parkinson's disease patients with deep brain stimulation

Behavioural Brain Research

Volumn 250, Issue , 2013, Pages 199-205

  Keitel, Ariane ^a   Wojtecki, Lars ^a,b   Hirschmann, Jan ^a,b   Hartmann, Christian J ^a,b   Ferrea, Stefano ^a,b   Südmeyer, Martin ^a,b   Schnitzler, Alfons ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Deep brain stimulation; Expectation; Nocebo; Parkinson's disease; Placebo; Verbal fluency

Indexed keywords

ANTIPARKINSON AGENT;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; EXECUTIVE FUNCTION; EXPECTATION; FEMALE; FINGER; HAND MOVEMENT; HUMAN; KINEMATICS; LEARNING; MALE; MATTIS DEMENTIA RATING SCALE; MOTOR PERFORMANCE; MOTOR SYSTEM; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NOCEBO EFFECT; PARKINSON DISEASE; PLACEBO EFFECT; PRIORITY JOURNAL; SEMANTICS; SUBTHALAMIC NUCLEUS; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; VERBAL FLUENCY;

ADULT; AGED; COGNITION DISORDERS; DEEP BRAIN STIMULATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PLACEBO EFFECT; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SUBTHALAMIC NUCLEUS; VERBAL LEARNING;

EID: 84878676097     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.04.051     Document Type: Article

References (31)

1. Benedetti F., Carlino E., Pollo A. How placebos change the patient's brain. Neuropsychopharmacology 2011, 36:339-354.
2. Enck P., Benedetti F., Schedlowski M. New insights into the placebo and nocebo responses. Neuron 2008, 59:195-206.
3. de la Fuente-Fernandez R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., Stoessl A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001, 293:1164-1166.
4. Lidstone S.C., Schulzer M., Dinelle K., Mak E., Sossi V., Ruth T.J., et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Archives of General Psychiatry 2010, 67:857-865.
5. Benedetti F., Colloca L., Torre E., Lanotte M., Melcarne A., Pesare M., et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nature Neuroscience 2004, 7:587-588.
6. Goetz C.G., Wuu J., McDermott M.P., Adler C.H., Fahn S., Freed C.R., et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Movement Disorders 2008, 23:690-699.
7. Mercado R., Constantoyannis C., Mandat T., Kumar A., Schulzer M., Stoessl A.J., et al. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. Movement Disorders 2006, 21:1457-1461.
8. Benedetti F., Pollo A., Lopiano L., Lanotte M., Vighetti S., Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. Journal of Neuroscience 2003, 23:4315-4323.
9. Pollo A., Torre E., Lopiano L., Rizzone M., Lanotte M., Cavanna A., et al. Expectation modulates the response to subthalamic nucleus stimulation in Parkinsonian patients. Neuroreport 2002, 13:1383-1386.
10. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. New England Journal of Medicine 2006, 355:896-908.
11. Weaver F.M., Follett K., Stern M., Hur K., Harris C., Marks W.J., et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. Journal of the American Medical Association 2009, 301:63-73.
12. Schüpbach W.M., Rau J., Knudsen K., Volkmann J., Krack P., Timmermann L., et al. Neurostimulation for Parkinson's disease with early motor complications. New England Journal of Medicine 2013, 368:610-622.
13. Timmermann L., Braun M., Groiss S., Wojtecki L., Ostrowski S., Krause H., et al. Differential effects of levodopa and subthalamic nucleus deep brain stimulation on bradykinesia in Parkinson's disease. Movement Disorders 2008, 23:218-227.
14. Wenzelburger R., Kopper F., Zhang B.R., Witt K., Hamel W., Weinert D., et al. Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movements. Movement Disorders 2003, 18:1162-1169.
15. Parsons T.D., Rogers S.A., Braaten A.J., Woods S.P., Troster A.I. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurology 2006, 5:578-588.
16. Saez-Zea C., Escamilla-Sevilla F., Katati M.J., Minguez-Castellanos A. Cognitive Effects of subthalamic nucleus stimulation in Parkinson's disease: a controlled study. European Neurology 2012, 68:361-366.
17. Wojtecki L., Timmermann L., Jorgens S., Sudmeyer M., Maarouf M., Treuer H., et al. Frequency-dependent reciprocal modulation of verbal fluency and motor functions in subthalamic deep brain stimulation. Archives of Neurology 2006, 63:1273-1276.
18. Benedetti F., Amanzio M., Baldi S., Casadio C., Maggi G. Inducing placebo respiratory depressant responses in humans via opioid receptors. European Journal of Neuroscience 1999, 11:625-631.
19. Mattis S. Dementia Rating Scale 1988, Psychological Assessment Resources, Odessa, FL.
20. Beck A.T. Beck Depression Inventory - Manual 1987, The Psychological Association, San Antonio.
21. Kumar R. Methods of programming and patient management with deep brain stimulation. Surgical Treatment of Parkinson's Disease and Other Movement Disorders 2002, 189-212. Humana Press, Totowa, NJ. D. Tarsy, V.L. Vitek, A.M. Lozano (Eds.).
22. Goetz C.G., Tilley B.C., Shaftman S.R., Stebbins G.T., Fahn S., Martinez-Martin P., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disorders 2008, 23:2129-2170.
23. Laux L., Glanzmann P., Schaffner P., Spielberger C.D. State-Trait-Angstinventar 1981, Beltz, Weinheim.
24. Horne R., Weinman J., Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology & Health 1999, 14:1-24.
25. Kaptchuk T.J., Kelley J.M., Deykin A., Wayne P.M., Lasagna L.C., Epstein I.O., et al. Do "placebo responders" exist?. Contemporary Clinical Trials 2008, 29:587-595.
26. Enck P., Bingel U., Schedlowski M., Rief W. The placebo response in medicine: minimize, maximize or personalize. Nature Reviews Drug Discovery 2013, 12:191-204.
27. Strafella A.P., Ko J.H., Monchi O. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation. Neuroimage 2006, 31:1666-1672.
28. Kalbe E., Voges J., Weber T., Haarer M., Baudrexel S., Klein J.C., et al. Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease. Neurology 2009, 72:42-49.
29. Schroeder U., Kuehler A., Lange K.W., Haslinger B., Tronnier V.M., Krause M., et al. Subthalamic nucleus stimulation affects a frontotemporal network: a PET study. Annals of Neurology 2003, 54:445-450.
30. Colloca L., Sigaudo M., Benedetti F. The role of learning in nocebo and placebo effects. Pain 2008, 136:211-218.
31. Colloca L., Petrovic P., Wager T.D., Ingvar M., Benedetti F. How the number of learning trials affects placebo and nocebo responses. Pain 2010, 151:430-439.